Kindred Biosciences, Inc. (NASDAQ:KIN) has earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $8.67.
Separately, Zacks Investment Research upgraded shares of Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.50 price target for the company in a research note on Wednesday, September 6th.
Kindred Biosciences (NASDAQ KIN) remained flat at $7.40 on Friday. 64,244 shares of the company’s stock were exchanged. The firm’s market capitalization is $205.99 million. Kindred Biosciences has a one year low of $3.90 and a one year high of $9.65. The company has a 50-day moving average of $7.73 and a 200-day moving average of $7.43.
Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. On average, equities research analysts forecast that Kindred Biosciences will post ($1.27) EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors bought a new stake in shares of Kindred Biosciences in the 2nd quarter worth $100,000. JPMorgan Chase & Co. bought a new stake in shares of Kindred Biosciences in the 2nd quarter worth $119,000. Trexquant Investment LP bought a new stake in shares of Kindred Biosciences in the 2nd quarter worth $120,000. OxFORD Asset Management LLP bought a new stake in shares of Kindred Biosciences in the 2nd quarter worth $128,000. Finally, State of Wisconsin Investment Board bought a new stake in shares of Kindred Biosciences in the 2nd quarter worth $129,000. Hedge funds and other institutional investors own 60.37% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Kindred Biosciences, Inc. (KIN) Receives Average Recommendation of “Buy” from Brokerages” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/27/kindred-biosciences-inc-kin-receives-average-recommendation-of-buy-from-brokerages.html.
About Kindred Biosciences
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.